Keep the air clean
IT is estimated that over onethird (2.3 billion) of the world population is infected with tuberculosis (TB) and do not know it. This condition is commonly referred to as “Latent TB infection”. Most of the time, the immune system can fight the bacteria to stop them from growing.
However, once the immune system is weakened, the germ starts multiplying and can quickly develop into an active TB disease.
About 10% of Latent TB infection eventually develops and becomes Active TB. Those at higher risk are individuals with medical conditions that weaken the immune system as well as infants with immature immune systems. In 2015, there were one million new TB cases among children.
A person with Active TB will infect an average of 10 to 15 people per year.
Without proper treatment, Active TB can further develop acquired drug-resistant TB. If left untreated, TB can be fatal.
Keeping in mind the burden of TB, Sharp decided to investigate the efficiency of its proprietary air purification Plasmacluster Ion (PCI) technology to control the spread of TB.
In collaboration with the National Centre of Tuberculosis and Lung Disease (NCTLD) in Georgia, a clinical study was conducted by placing high ion density PCI devices in a designated floor in the hospital.
This resulted with an impressive 75% decreased risk of TB for healthcare workers and 78% in acquired drug resistance on TB patients.
As a support for combating TB in Malaysia, Sharp made a contribution to the Malaysian Association for the Prevention of Tuberculosis (MAPTB) with 10 units of PCI air purifier for a healthier environment. MAPTB functions as an organisation for the prevention, control and treatment of TB in Malaysia.
Sharp Plasmacluster: Trusted by many
Sharp’s PCI technology mechanism functions by dispersing positive hydrogen (H+) and negative oxygen (O-) ions in to the air simultaneously. These are the same ions found in abundance in the natural environment, such as forests and mountains and are completely harmless to humans.
The ions deactivate airborne contaminants by attaching on the contaminants while extracting a hydrogen compound to break down the protein membrane.
This results in water (H O) molecules, which are returned back into the air. Aside from suppressing airborne virus and bacteria, PCI also suppresses airborne and proliferating mould, unpleasant odour and allergens such as dust mites and its faeces.
To further demonstrate the efficacy of PCI, Sharp has adopted the concept of “academic marketing” by collaborating with independent scientific research organisations around the world.
The aim for this approach is that while PCI has achieved the ideals it had been designed for; it still needed to be proven that the results were genuine and trusted around the world.
The effectiveness of PCI has been tested in over 28 institutes worldwide with studies on controlling hazardous substances such as influenza viruses and reducing the risk of tracheal inflammation in childhood asthma patients. With the intense research on PCI, we can expect further development from Sharp’s PCI technology.
For details, call 03-5190 5369 or visit www.sharp.com.my, or on Facebook at Sharp Plasmacluster Malaysia.